141 related articles for article (PubMed ID: 26339915)
1. [Molecular diagnostics of lung cancer].
Ryska A; Dziadziuszko R; Olszewski W; Berzinec P; Öz B; Gottfried M; Cufer T; Samarzija M; Plank L; Ostoros G; Tímár J
Magy Onkol; 2015 Sep; 59(3):259-66. PubMed ID: 26339915
[TBL] [Abstract][Full Text] [Related]
2. [Molecular pathology of lung cancer: key to personalized medicine].
Cheng L; Li Y; Zhang SB; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
[No Abstract] [Full Text] [Related]
3. [Criteria of the molecular pathology testing of lung cancer].
Tímár J
Magy Onkol; 2014 Jun; 58(2):139-42. PubMed ID: 25010763
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
Jones S
Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
[No Abstract] [Full Text] [Related]
5. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
6. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
7. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
9. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
Gridelli C; de Marinis F; Ardizzoni A; Novello S; Fontanini G; Cappuzzo F; Grossi F; Santo A; Cortinovis D; Favaretto A; Lorusso V; Galetta D; Siena S; Bettini A; Iurlaro M; Caprioli A;
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1783-93. PubMed ID: 24903964
[TBL] [Abstract][Full Text] [Related]
10. [Basic principles for the prevention, diagnosis and therapy of lung cancer].
Gyula O; András B; Zoltán B; Katalin B; Attila C; Janos F; Maria G; Akos H; Lászlo K; Lászlo K; Gabor K; Gyorgy L; Judit M; Tamas MF; Zsuzsa M; Pál R; Zsolt O; János S; Zoltán S; István S; Klára S; Jozsef T; Edina T;
Magy Onkol; 2012 May; 56(2):114-32. PubMed ID: 22724157
[No Abstract] [Full Text] [Related]
11. Are all KRAS mutations created equal?
Stinchcombe TE; Der CJ
Lancet Oncol; 2011 Aug; 12(8):717-8. PubMed ID: 21782508
[No Abstract] [Full Text] [Related]
12. ALK, lung cancer, and personalized therapy: portent of the future?
Garber K
J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
[No Abstract] [Full Text] [Related]
13. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
14. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
17. [Personalized medicine in non-small-cell carcinoma].
Iwama E; Takayama K; Baba E; Nakanishi Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):57-66. PubMed ID: 25000657
[No Abstract] [Full Text] [Related]
18. New targets and new mechanisms in lung cancer.
Carrizosa DR; Mileham KF; Haggstrom DE
Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
[TBL] [Abstract][Full Text] [Related]
19. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
de Mello RA; Madureira P; Carvalho LS; Araújo A; O'Brien M; Popat S
Pharmacogenomics; 2013 Nov; 14(14):1765-77. PubMed ID: 24192124
[TBL] [Abstract][Full Text] [Related]
20. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Ou SH; Bazhenova L; Camidge DR; Solomon BJ; Herman J; Kain T; Bang YJ; Kwak EL; Shaw AT; Salgia R; Maki RG; Clark JW; Wilner KD; Iafrate AJ
J Thorac Oncol; 2010 Dec; 5(12):2044-6. PubMed ID: 21102269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
